In CLL, two PI3K inhibitors, idelalisib and duvelisib, have been approved; however, despite demonstrating similar efficacy, they are used much less often than BTKi due to their poorer toxicity profile, including mainly autoimmune complications such as colitis, pneumonitis and increased susceptibility for infections. This evidence concerns the gene PIK3CD and pneumonitis.